Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease

scientific article

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1161/CIRCULATIONAHA.108.844506
P932PMC publication ID2740903
P698PubMed publication ID19414634
P5875ResearchGate publication ID24400964

P50authorChristopher deFilippiQ43249939
Udo HoffmannQ63022682
James JanuzziQ63144011
Myles WolfQ90101213
P2093author name stringThomas J Wang
Orlando M Gutiérrez
Ammar Sarwar
Erin Coglianese
Gina Collerone
Karen Laliberte
Kelsey Smith
Robert Christenson
Tamara Isakova
P2860cites workCoronary Artery Calcium Score Combined With Framingham Score for Risk Prediction in Asymptomatic IndividualsQ22252997
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalizationQ28283679
How fibroblast growth factor 23 worksQ28301673
Fibroblast growth factor-2 mediates pressure-induced hypertrophic responseQ28343582
Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vitroQ28565692
Prevalence of chronic kidney disease in the United StatesQ29614191
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study GroupQ29614889
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysisQ33932297
Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23Q34075026
Left ventricular hypertrophy in the renal patientQ34228252
Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and PreventiQ34272627
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney diseaseQ34557934
Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular functionQ36095572
The mechanism of phosphorus as a cardiovascular risk factor in CKDQ36677622
Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissuesQ38474392
Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled studyQ40403628
Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for interventionQ40949366
Myocardial interstitial fibrosis in experimental uremia--implications for cardiac complianceQ41979332
Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjectsQ43573502
Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systemsQ45059018
Chronic kidney disease predicts cardiovascular diseaseQ45072901
Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.Q45197408
Serum phosphate levels and mortality risk among people with chronic kidney diseaseQ45198981
Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequencesQ46318788
Prevalence and associations of coronary artery calcification in patients with stages 3 to 5 CKD without cardiovascular disease.Q46533837
Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patientsQ46631801
Relation between serum phosphate level and cardiovascular event rate in people with coronary diseaseQ46772376
The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study.Q46987014
N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patientsQ48552289
Mineral metabolism, mortality, and morbidity in maintenance hemodialysisQ50144395
The long-term behavior and predictors of left ventricular hypertrophy in hemodialysis patients.Q50777435
Quantification of coronary artery calcium using ultrafast computed tomography.Q52867038
Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function.Q53455976
Adult cardiomyocytes express functional high-affinity receptors for basic fibroblast growth factor.Q54173211
Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension.Q54269247
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of EchocardioQ57217547
Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD) StudyQ59575076
Association between Chronic Kidney Disease and Coronary Artery Calcification: The Dallas Heart StudyQ60777269
Improved electrocardiographic diagnosis of left ventricular hypertrophyQ72759885
Trophic effect of human pericardial fluid on adult cardiac myocytes. Differential role of fibroblast growth factor-2 and factors related to ventricular hypertrophyQ73833050
Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysisQ77309263
Basic fibroblast growth factor induces myocardial hypertrophy following acute infarction in ratsQ77481811
Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patientsQ79478108
Coronary calcification improves cardiovascular risk prediction in the elderlyQ80357431
Altered sodium intake affects plasma concentrations of BNP but not proBNP in healthy individuals and patients with compensated heart failureQ81453785
Impact of left ventricular hypertrophy on survival in end-stage renal diseaseQ93520188
P433issue19
P407language of work or nameEnglishQ1860
P921main subjectleft ventricular hypertrophyQ1628627
P304page(s)2545-2552
P577publication date2009-05-04
P1433published inCirculationQ578091
P1476titleFibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease
P478volume119

Reverse relations

cites work (P2860)
Q357558171,25-Dihydroxyvitamin D to PTH(1-84) Ratios Strongly Predict Cardiovascular Death in Heart Failure
Q37552700A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease
Q38140738A short story of Klotho and FGF23: a deuce of dark side or the savior?
Q36348861Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy
Q34683694Active vitamin D and accelerated progression of aortic stiffness in hemodialysis patients: a longitudinal observational study.
Q47098883Albuminuria and kidney function as prognostic marker of left ventricular mass among South Asians with hypertension
Q35782011Altered Osteocyte-Specific Protein Expression in Bone after Childhood Solid Organ Transplantation
Q34641464An update on uremic toxins
Q34663898Arterial klotho expression and FGF23 effects on vascular calcification and function
Q36072709Association between FGF23, α-Klotho, and Cardiac Abnormalities among Patients with Various Chronic Kidney Disease Stages
Q34988878Association between circulating fibroblast growth factor 23, α-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients
Q40643620Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study
Q88517168Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial
Q52667905Association of Fibroblast Growth Factor 23 With Risk of Incident Coronary Heart Disease in Community-Living Adults.
Q50912508Association of Serum Phosphorus Concentration with Mortality and Graft Failure among Kidney Transplant Recipients.
Q40229714Association of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients
Q40106923Association of pre-operative estimated GFR on post-operative pulmonary complications in laparoscopic surgeries.
Q89260331Association of serum intact fibroblast growth factor 23 with left ventricular mass and different echocardiographic findings in patients on hemodialysis
Q34204949Association of serum levels of FGF23 and α-Klotho with glomerular filtration rate and proteinuria among cardiac patients
Q37126261Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure
Q36044367Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease
Q36227387Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease
Q92157066Associations of plasma fibroblast growth factor 23 and other markers of chronic kidney disease-Mineral and bone disorder with all-cause mortality in South African patients on maintenance dialysis: A 3-year prospective cohort study
Q35875497Associations of socioeconomic status and processed food intake with serum phosphorus concentration in community-living adults: the Multi-Ethnic Study of Atherosclerosis (MESA).
Q42870432Asymptomatic Ventricular Arrhythmia and Clinical Outcomes in Chronic Kidney Disease: A Pilot Study
Q50636871Baseline FGF23 is Associated with Cardiovascular Outcome in Incident PD Patients.
Q92153321Bone and heart health in chronic kidney disease: role of dentin matrix protein 1
Q34261737Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients
Q64054921Bone marrow and plasma FGF-23 in heart failure patients: novel insights into the heart-bone axis
Q33974636CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder
Q38576402Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures
Q46432103Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism
Q48038085Calcium Homeostasis in Health and in Kidney Disease
Q27687570Calcium and phosphate impact cardiovascular risk
Q38941532Calcium as a cardiovascular toxin in CKD-MBD.
Q26863412Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney disease
Q92070155Cardiac FGF23: a new player in myocardial infarction
Q38977291Cardiac actions of fibroblast growth factor 23.
Q57452637Cardioprotective Effects of Paricalcitol Alone and in Combination With FGF23 Receptor Inhibition in Chronic Renal Failure: An Experimental and Clinical Studies
Q35893998Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia
Q58773641Cardiotoxicity of Uremic Toxins: A Driver of Cardiorenal Syndrome
Q46002983Cardiovascular Effects of Renal Distal Tubule Deletion of the FGF Receptor 1 Gene.
Q58770788Cardiovascular Interactions between Fibroblast Growth Factor-23 and Angiotensin II
Q27024043Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular Disease
Q38025185Cardiovascular disease in chronic kidney disease: untying the Gordian knot
Q101038925Cardiovascular disease risk assessment in patients with familial Mediterranean fever related renal amyloidosis
Q38052430Cardiovascular risk assessment in children with chronic kidney disease
Q37670438Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease Stages 3 and 4.
Q52604286Changes in Biomarker Profile and Left Ventricular Hypertrophy Regression: Results from the Frequent Hemodialysis Network Trials.
Q37483194Changes in Serum Concentrations of Fibroblast Growth Factor 23 and Soluble Klotho in Hemodialysis Patients after Total Parathyroidectomy.
Q33937415Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial
Q90419329Changes in serum and intracardiac fibroblast growth factor 23 during the progression of left ventricular hypertrophy in hypertensive model rats
Q89762306CharXgen-Activated Bamboo Charcoal Encapsulated in Sodium Alginate Microsphere as the Absorbent of Uremic Toxins to Retard Kidney Function Deterioration
Q37053525Characterisation of cardiomyopathy by cardiac and aortic magnetic resonance in patients new to hemodialysis
Q89545116Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship?
Q38016491Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications
Q34402661Chronic kidney disease: mineral and bone disorder in children
Q34739121Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study
Q84847501Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism
Q57218945Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism
Q46921995Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism
Q37993874Cinacalcet: will it play a role in reducing cardiovascular events?
Q28477784Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese
Q54965740Circulating Fibroblast Growth Factor-23 Levels are Associated with an Increased Risk of Anemia Development in Patients with Nondialysis Chronic Kidney Disease.
Q33736093Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active
Q34981550Circulating fibroblast growth factor 23 is associated with angiographic severity and extent of coronary artery disease
Q34989319Clinical Significance of FGF-23 in Patients with CKD.
Q56761591Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients
Q38784139Clinical features of CKD-MBD in Japan: cohort studies and registry
Q37641052Clinical relevance of FGF-23 in chronic kidney disease
Q38096829Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin
Q48951447Correction of hyperphosphatemia suppresses cardiac remodeling in uremic rats.
Q35067500Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease
Q90450534Current Understanding of Mineral and Bone Disorders of Chronic Kidney Disease and the Scientific Grounds on the Use of Exogenous Parathyroid Hormone in Its Management
Q64087850DMP1 prevents osteocyte alterations, FGF23 elevation and left ventricular hypertrophy in mice with chronic kidney disease
Q39249797Decreased expression of Klotho in cardiac atria biopsy samples from patients at higher risk of atherosclerotic cardiovascular disease
Q52673652Deleterious effects of phosphate on vascular and endothelial function via disruption to the nitric oxide pathway.
Q35895880Determinants of left ventricular mass in patients on hemodialysis: Frequent Hemodialysis Network (FHN) Trials.
Q35953344Dietary phosphorus intake and mortality in moderate chronic kidney disease: NHANES III.
Q36728820Dietary phosphorus is associated with greater left ventricular mass
Q87375449Dietary phosphorus restriction by a standard low-protein diet decreased serum fibroblast growth factor 23 levels in patients with early and advanced stage chronic kidney disease
Q37553097Disordered FGF23 and mineral metabolism in children with CKD
Q37801814Disorders of phosphorus homeostasis
Q37891153Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?
Q35646353Effect of High-Flux Dialysis on Circulating FGF-23 Levels in End-Stage Renal Disease Patients: Results from a Randomized Trial
Q53822817Effect of combined vitamin D receptor activator and lanthanum carbonate on serum fibroblast growth factor 23 level in predialysis patients (CVD-LAF study): design and method.
Q33914268Effect of niacin on FGF23 concentration in chronic kidney disease
Q41113729Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure
Q36614486Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients
Q46248791Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice
Q34639705Effects of dietary phosphate and calcium intake on fibroblast growth factor-23
Q90209853Effects of erythropoietin on fibroblast growth factor 23 in mice and humans
Q57214530Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients
Q30658399Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease
Q57214044Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients
Q34755816Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease
Q53241475Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients.
Q34428293Elevated cardiac markers in chronic kidney disease as a consequence of hyperphosphatemia-induced cardiac myocyte injury
Q30427104Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality
Q49152067Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failure
Q38674256Elevation of plasma oncostatin M in heart failure
Q43236381Emerging risk factors and markers of chronic kidney disease progression
Q53810866Enhanced FGF23 production in mice expressing PI3K-insensitive GSK3 is normalized by β-blocker treatment.
Q35997370Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease.
Q36495082Estimated GFR and Subsequent Higher Left Ventricular Mass in Young and Middle-Aged Adults With Normal Kidney Function: The Coronary Artery Risk Development in Young Adults (CARDIA) Study
Q84904076Evaluation of a new automated chemiluminescence immunoassay for FGF23
Q48191834Evaluation of potential long-term changes in endothelial functions and basic echocardiographic parameters in unilateral nephrectomy patients
Q91142496Evolving concepts in the pathogenesis of uraemic cardiomyopathy
Q38960643FGF-23 and cardiovascular disease: review of literature.
Q35647125FGF-23 and cognitive performance in hemodialysis patients
Q39866881FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment
Q36443208FGF-23 and the progression of coronary arterial calcification in patients new to dialysis
Q42976674FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease
Q34639537FGF-23 as a Predictor of Renal Outcome in Diabetic Nephropathy
Q35030290FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients
Q35272291FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis
Q37291894FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock
Q52985054FGF-23 levels are associated with vascular calcification, but not with atherosclerosis, in hemodialysis patients.
Q52977075FGF-23 levels in patients with critical carotid artery stenosis.
Q86525641FGF-23, vascular calcification, and cardiovascular diseases in chronic hemodialysis patients
Q35827508FGF-23, α-Klotho Gene Polymorphism and Their Relationship with the Markers of Bone Metabolism in Chronic Peritoneal Dialysis Patients
Q35156017FGF-23: More than a regulator of renal phosphate handling?
Q38031216FGF-23: the rise of a novel cardiovascular risk marker in CKD.
Q88523645FGF23 (Fibroblast Growth Factor-23) and Incident Hypertension in Young and Middle-Aged Adults: The CARDIA Study
Q53088891FGF23 affects the lineage fate determination of mesenchymal stem cells.
Q46192114FGF23 and Left Ventricular Hypertrophy in Children with CKD.
Q37228152FGF23 and mineral metabolism in the early post-renal transplantation period
Q27687769FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease
Q91697808FGF23 expression is stimulated in transgenic α-Klotho longevity mouse model
Q38728860FGF23 from bench to bedside.
Q41186366FGF23 in kidney transplant: the strange case of Doctor Jekyll and Mister Hyde
Q91410209FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice
Q34028891FGF23 induces left ventricular hypertrophy
Q34035797FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy
Q53189719FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages.
Q36068303FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality
Q37662106FGF23 promotes myocardial fibrosis in mice through activation of β-catenin
Q35917428FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy
Q90195274FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis
Q33694566FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
Q38111898FGF23: a mature renal and cardiovascular risk factor?
Q46004871Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.
Q88284298Fibroblast Growth Factor 23: A Biomarker of Kidney Function Decline
Q42234272Fibroblast Growth Factor and Mineral Metabolism Parameters among Prevalent Kidney Transplant Patients
Q28075648Fibroblast Growth Factor-23-A Potential Uremic Toxin
Q36067879Fibroblast growth factor 23 and Inflammation in CKD
Q48461689Fibroblast growth factor 23 and Klotho as cardiovascular risk factors in heart transplant recipients
Q35965337Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease
Q37280819Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation
Q34281341Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease
Q41091515Fibroblast growth factor 23 and heart failure: the plot thickens
Q34828731Fibroblast growth factor 23 and incident CKD in type 2 diabetes.
Q84403337Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis
Q47817743Fibroblast growth factor 23 and left ventricular mass index in maintenance hemodialysis patients: standard versus long nocturnal hemodialysis
Q40268402Fibroblast growth factor 23 and parathyroid hormone predict extent of aortic valve calcifications in patients with mild to moderate chronic kidney disease
Q35019943Fibroblast growth factor 23 and risk of incident stroke in community-living adults
Q34027316Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease
Q51199021Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease.
Q35797940Fibroblast growth factor 23 and sudden versus non-sudden cardiac death: the Cardiovascular Health Study
Q37913097Fibroblast growth factor 23 as a phosphotropic hormone and beyond
Q40279706Fibroblast growth factor 23 correlates with volume status in haemodialysis patients and is not reduced by haemodialysis
Q34280125Fibroblast growth factor 23 in acute kidney injury
Q35008805Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial
Q37832285Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications
Q34557041Fibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: a cross-sectional study
Q35099518Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease
Q36901897Fibroblast growth factor 23 is not associated with and does not induce arterial calcification
Q35157648Fibroblast growth factor 23 predicts left ventricular mass and induces cell adhesion molecule formation
Q48891787Fibroblast growth factor 23 signaling in hippocampal cells: impact on neuronal morphology and synaptic density.
Q36791903Fibroblast growth factor 23, Klotho, and disordered mineral metabolism in chronic kidney disease: unraveling the intricate tapestry of events and implications for therapy
Q37071263Fibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: the cardiovascular health study
Q35664606Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study
Q36476324Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD.
Q37342971Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults
Q34669005Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs).
Q37589683Fibroblast growth factor 23, the ankle-brachial index, and incident peripheral artery disease in the Cardiovascular Health Study
Q96647282Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction
Q90043642Fibroblast growth factor 23: are we ready to use it in clinical practice?
Q38072361Fibroblast growth factor 23: associations with cardiovascular disease and mortality in chronic kidney disease
Q46567248Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients
Q34039877Fibroblast growth factor-23 and cardiac structure and function
Q37524119Fibroblast growth factor-23 and cardiovascular events in CKD.
Q36095111Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study).
Q33988990Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study
Q33940724Fibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS).
Q35021985Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study
Q87406390Fibroblast growth factor-23 and renin-angiotensin system levels in vitamin-D-dependent rickets type I
Q40115641Fibroblast growth factor-23 but not sKlotho levels are related to diastolic dysfunction in type 1 diabetic patients with early diabetic nephropathy
Q35967107Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease
Q34255342Fibroblast growth factor-23 in obese, normotensive adolescents is associated with adverse cardiac structure
Q44716347Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease
Q45271516Fibroblast growth factor-23 levels are associated with uric acid but not carotid intima media thickness in renal transplant recipients
Q54700038Fibroblast growth factor-23 levels are associated with vascular calcifications in peritoneal dialysis patients.
Q34421217Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease
Q37162723Fibroblast growth factor-23: what we know, what we don't know, and what we need to know
Q58760089Fibroblast growth factor23 is associated with axonal integrity and neural network architecture in the human frontal lobes
Q28084197Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21
Q41200048Genetic Ablation of Fgf23 or Klotho Does not Modulate Experimental Heart Hypertrophy Induced by Pressure Overload.
Q35138993Heart failure and atrial fibrillation: from basic science to clinical practice
Q55399715High Fibroblast Growth Factor 23 concentrations in experimental renal failure impair calcium handling in cardiomyocytes.
Q30564821High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III.
Q47843993High serum phosphorus and FGF 23 levels are associated with progression of coronary calcifications
Q36287699High-Flux Hemodialysis Benefits Hemodialysis Patients by Reducing Serum FGF-23 Levels and Reducing Vascular Calcification.
Q33600110Higher fibroblast growth factor-23 concentrations associate with left ventricular systolic dysfunction in dialysis patients
Q95407461Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community
Q43207404Hunt for the culprit of cardiovascular injury in kidney disease
Q89161363Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature
Q55413743Impact of Altered Mineral Metabolism on Pathological Cardiac Remodeling in Elevated Fibroblast Growth Factor 23.
Q35837789Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients
Q35207828Impact of westernization on fibroblast growth factor 23 levels among individuals of African ancestry
Q52720297Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH.
Q36156920Increased FGF23 serum level is associated with unstable carotid plaque in type 2 diabetic subjects with internal carotid stenosis
Q45339625Increased Levels of sRAGE in Diabetic CKD-G5D Patients: A Potential Protective Mechanism against AGE-Related Upregulation of Fibroblast Growth Factor 23 and Inflammation.
Q52894312Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
Q48006325Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease
Q41305100Inflammation but not obesity or insulin resistance is associated with increased plasma fibroblast growth factor 23 concentration in the elderly.
Q41217019Integrative bioinformatics analysis of proteins associated with the cardiorenal syndrome
Q39456034Interorgan handling of fibroblast growth factor-23 in humans.
Q34040279Intersection of cardiovascular disease and kidney disease: atrial fibrillation
Q48045737Intracellular calcium increases in vascular smooth muscle cells with progression of chronic kidney disease in a rat model
Q34650666Iron and obesity status-associated insulin resistance influence circulating fibroblast-growth factor-23 concentrations
Q92562108Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study
Q39440902Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?
Q35207839Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?
Q37760853Is Fibroblast Growth Factor-23 a novel marker for phosphate burden in chronic kidney disease with prognostic implications?
Q37851395Is fibroblast growth factor 23 a harbinger of mortality in CKD?
Q38258133Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease
Q53342879Is there a role for newer biomarkers in chronic kidney disease-mineral and bone disorder management?
Q55300798Klotho is upregulated in human cardiomyopathy independently of circulating Klotho levels.
Q91659301Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial
Q64231913Lack of Awareness of Dietary Sources of Phosphorus Is a Clinical Concern
Q38444264Left Ventricular Diastolic Dysfunction in End-Stage Kidney Disease: Pathogenesis, Diagnosis, and Treatment
Q33791650Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease.
Q36172106Long term evolution of endothelial function during kidney transplantation.
Q58946285Longitudinal Analysis of Vascular Function and Biomarkers of Metabolic Bone Disorders before and after Renal Transplantation
Q40500215Longitudinal assessment of cardiac morphology and function following kidney transplantation
Q36227410Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease
Q36417886Low Vitamin D and High Fibroblast Growth Factor 23 Serum Levels Associate with Infectious and Cardiac Deaths in the HEMO Study
Q37029683Low body mass index and dyslipidemia in dialysis patients linked to elevated plasma fibroblast growth factor 23.
Q41003926Markers of bone remodeling are associated with arterial stiffness in renal transplanted subjects
Q40721152Markers of kidney disease and risk of subclinical and clinical heart failure in African Americans: the Jackson Heart Study
Q49620885MicroRNA-21 regulates peroxisome proliferator-activated receptor alpha, a molecular mechanism of cardiac pathology in Cardiorenal Syndrome Type 4.
Q36123640Mineral (Mal)Adaptation to Kidney Disease--Young Investigator Award Address: American Society of Nephrology Kidney Week 2014
Q89996076Mineral Metabolism Disturbances and Arteriovenous Fistula Maturation
Q37938689Mineral and bone disorders in children with chronic kidney disease
Q36994038Mineral metabolic abnormalities and mortality in dialysis patients
Q34550213Mineral metabolism and outcomes in chronic kidney disease stage 2-4 patients.
Q47132894New Insights into the Mechanism of Action of Soluble Klotho
Q30979522Non-Linear Heart Rate Variability Indices in the Frequent Hemodialysis Network Trials of Chronic Hemodialysis Patients
Q57796697Non-renal-Related Mechanisms of FGF23 Pathophysiology
Q36225208Novel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease
Q38245327Novel metabolic biomarkers of cardiovascular disease
Q49166621Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes
Q55221465Paracrine Effects of FGF23 on the Heart.
Q51714847Parathormone Levels Are Independently Associated with the Presence of Left Ventricular Hypertrophy in Patients with Coronary Artery Disease.
Q90462704Parathyroid Hormone: A Uremic Toxin
Q34989448Parathyroid scintigraphy in renal hyperparathyroidism: the added diagnostic value of SPECT and SPECT/CT.
Q35069203Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion
Q37690771Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats
Q26853186Pathophysiological roles of FGF signaling in the heart
Q49908584Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease
Q37520430Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies
Q34213752Pharmacology, efficacy and safety of oral phosphate binders
Q54357184Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT).
Q36965142Phosphate Toxicity in CKD: The Killer among Us
Q55098165Phosphate and Cardiovascular Disease beyond Chronic Kidney Disease and Vascular Calcification.
Q24610674Phosphate and FGF-23
Q33566596Phosphate and cardiovascular disease
Q38079128Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children
Q58797979Phosphate control in reducing FGF23 levels in hemodialysis patients
Q38049170Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate
Q38009044Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk
Q38060627Phosphate is a vascular toxin
Q35998095Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study
Q37492019Phosphate: an old bone molecule but new cardiovascular risk factor
Q36236289Phosphocalcic Markers and Calcification Propensity for Assessment of Interstitial Fibrosis and Vascular Lesions in Kidney Allograft Recipients
Q42123269Phosphorus metabolism in chronic kidney disease
Q35025469Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease
Q36520483Plasma FGF23 and Calcified Atherosclerotic Plaque in African Americans with Type 2 Diabetes Mellitus
Q33654616Plasma FGF23 and the risk of stroke: the Northern Manhattan Study (NOMAS)
Q85316417Plasma FGF23 levels and heart rate variability in patients with stage 5 CKD
Q64108575Plasma Fibroblast Growth Factor 23 Is Elevated in Pediatric Primary Hypertension
Q37240698Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study
Q86360000Plasma fibroblast growth factor 23 and risk of cardiovascular disease: results from the EPIC-Germany case-cohort study
Q85212298Plasma fibroblast growth factor‐23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients
Q30316351Potential Predictors of Plasma Fibroblast Growth Factor 23 Concentrations: Cross-Sectional Analysis in the EPIC-Germany Study
Q28468444Predictive Factors of One-Year Mortality in a Cohort of Patients Undergoing Urgent-Start Hemodialysis
Q33591588Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC).
Q85892981Preoperative plasma FGF23 levels predict acute kidney injury in children: results of a pilot study
Q59335712Quantitative Gadolinium-Free Cardiac Fibrosis Imaging in End Stage Renal Disease Patients Reveals A Longitudinal Correlation with Structural and Functional Decline
Q35860700Racial differences in markers of mineral metabolism in advanced chronic kidney disease
Q37248630Recent advances in the noninvasive diagnosis of renal osteodystrophy
Q37783496Reciprocal Control of 1,25-Dihydroxyvitamin D and FGF23 Formation Involving the FGF23/Klotho System
Q26860470Regulation and function of the FGF23/klotho endocrine pathways
Q35665003Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure
Q43109219Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship?
Q34479134Relationship between Fibroblast Growth Factor-23 and Mineral Metabolism in Chronic Kidney Disease
Q45030154Relationship between serum fibroblast growth factor-23 level and mortality in chronic hemodialysis patients
Q87311239Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease
Q53149178Relationship of fibroblast growth factor 23 with left ventricle mass index and coronary calcificaton in chronic renal disease.
Q100428073Relative overhydration is independently associated with left ventricular hypertrophy in dialysis naïve patients with stage 5 chronic kidney disease
Q92354701Removal of large middle molecules via haemodialysis with medium cut-off membranes at lower blood flow rates: an observational prospective study
Q34962806Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor
Q38042591Renalase, hypertension, and kidney - the discussion continues
Q38141236Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism.
Q34634066Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1.
Q38164437Risk of sudden cardiac death in chronic kidney disease
Q35755137Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models
Q55315635Role of Fibroblast Growth Factor-23 in Innate Immune Responses.
Q38200883Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.
Q33939707S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner
Q95411416Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
Q56109733Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men
Q84976574Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients
Q34254746Serum phosphorus and mortality in the Third National Health and Nutrition Examination Survey (NHANES III): effect modification by fasting.
Q90099487Short-Term Effects of Very-Low-Phosphate and Low-Phosphate Diets on Fibroblast Growth Factor 23 in Hemodialysis Patients: A Randomized Crossover Trial
Q26782946Significant roles of anti-aging protein klotho and fibroblast growth factor23 in cardiovascular disease
Q38847325Silent Cerebral Microbleeds and Longitudinal Risk of Renal and Cardiovascular Events in Patients with CKD.
Q89479278Sleep disordered breathing and fibroblast growth factor 23 in the Hispanic Community Health Study/Study of Latinos
Q35550609Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate
Q92663763Soluble Klotho is associated with mortality and cardiovascular events in hemodialysis
Q40478704Spleen contributes significantly to increased circulating levels of fibroblast growth factor 23 in response to lipopolysaccharide-induced inflammation.
Q64104905Sudden Cardiac Death in Dialysis: Arrhythmic Mechanisms and the Value of Non-invasive Electrophysiology
Q34500628Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation
Q64118923The EPO-FGF23 Signaling Pathway in Erythroid Progenitor Cells: Opening a New Area of Research
Q35914820The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease
Q93180147The FGF metabolic axis
Q38644586The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study
Q24625902The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis
Q38571195The PTH-Vitamin D-FGF23 axis
Q50101289The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease
Q52146506The Vitamin D Receptor Activator Maxacalcitol Provides Cardioprotective Effects in Diabetes Mellitus.
Q34022484The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study.
Q37296494The connection between dietary phosphorus, cardiovascular disease, and mortality: where we stand and what we need to know
Q38545213The dynamic skeleton
Q45134043The fibroblast growth factor-23 and Vitamin D emerge as nontraditional risk factors and may affect cardiovascular risk
Q38255386The impact of arteriovenous fistulae on the myocardium: the impact of creation and ligation in the transplant era.
Q48122785The impact of calcineurin inhibitors on neutrophil gelatinase-associated lipocalin and fibroblast growth factor 23 in long-term kidney transplant patients
Q38053246The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications
Q34027561The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation
Q38244314The role of bone in CKD-mediated mineral and vascular disease
Q36963471The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy
Q53989980The role of fibroblast growth factor-23 in cardiorenal syndrome.
Q26823897The role of phosphorus in the development and progression of vascular calcification
Q30234695The systemic nature of CKD.
Q33835743The use of fibroblast growth factor 23 testing in patients with kidney disease
Q38605457Therapeutic effect of CNP on renal osteodystrophy by antagonizing the FGF-23/MAPK pathway
Q38633258Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.
Q35588217Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD.
Q64990625Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study.
Q58578167Update on Chronic Kidney Disease Mineral and Bone Disorder in Cardiovascular Disease
Q36210285Update on fibroblast growth factor 23 in chronic kidney disease
Q37809763Uraemic vasculopathy in children with chronic kidney disease: prevention or damage limitation?
Q55496554Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation.
Q88172233Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction
Q34037021Vascular calcification in chronic kidney disease: role of disordered mineral metabolism
Q35278497Vascular calcification in patients with nondialysis CKD over 3 years
Q28071582Vascular calcification: When should we interfere in chronic kidney disease patients and how?
Q34385273Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects
Q88648846Vitamin D and Calcimimetics in Cardiovascular Disease
Q38624627Vitamin D and Heart Failure.
Q38878795Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats.
Q37737597Vitamin D, chronic kidney disease and survival: a pluripotent hormone or just another bone drug?
Q86277253[FGF23 and the heart]
Q39812781αKlotho and Chronic Kidney Disease

Search more.